Until now, most assays of GPCR function have been performed in whole cells or in transgenic animals, neither of which are amenable to high-throughput scale-up. In this issue, Vogel and coworkers ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.